GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lisata Therapeutics Inc (NAS:LSTA) » Definitions » Shiller PE Ratio

Lisata Therapeutics (Lisata Therapeutics) Shiller PE Ratio : (As of Apr. 27, 2024)


View and export this data going back to 1999. Start your Free Trial

What is Lisata Therapeutics Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Lisata Therapeutics Shiller PE Ratio Historical Data

The historical data trend for Lisata Therapeutics's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lisata Therapeutics Shiller PE Ratio Chart

Lisata Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Lisata Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Lisata Therapeutics's Shiller PE Ratio

For the Biotechnology subindustry, Lisata Therapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lisata Therapeutics's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lisata Therapeutics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Lisata Therapeutics's Shiller PE Ratio falls into.



Lisata Therapeutics Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Lisata Therapeutics's E10 for the quarter that ended in Dec. 2023 is calculated as:

For example, Lisata Therapeutics's adjusted earnings per share data for the three months ended in Dec. 2023 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-0.66/129.4194*129.4194
=-0.660

Current CPI (Dec. 2023) = 129.4194.

Lisata Therapeutics Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201403 -73.500 99.695 -95.415
201406 -60.000 100.560 -77.220
201409 -72.000 100.428 -92.785
201412 -46.500 99.070 -60.745
201503 -76.500 99.621 -99.382
201506 -57.600 100.684 -74.039
201509 -30.900 100.392 -39.835
201512 -94.050 99.792 -121.972
201603 -31.350 100.470 -40.383
201606 -19.950 101.688 -25.391
201609 -16.350 101.861 -20.773
201612 -8.100 101.863 -10.291
201703 -16.800 102.862 -21.137
201706 65.100 103.349 81.522
201709 -5.700 104.136 -7.084
201712 -5.700 104.011 -7.092
201803 -7.800 105.290 -9.588
201806 -6.300 106.317 -7.669
201809 -5.400 106.507 -6.562
201812 -5.400 105.998 -6.593
201903 -6.600 107.251 -7.964
201906 -7.350 108.070 -8.802
201909 -7.050 108.329 -8.423
201912 -7.200 108.420 -8.595
202003 -5.700 108.902 -6.774
202006 7.500 108.767 8.924
202009 -4.350 109.815 -5.127
202012 -5.100 109.897 -6.006
202103 -2.850 111.754 -3.300
202106 -1.500 114.631 -1.694
202109 -1.740 115.734 -1.946
202112 -1.690 117.630 -1.859
202203 -1.050 121.301 -1.120
202206 -1.640 125.017 -1.698
202209 -7.880 125.227 -8.144
202212 -0.758 125.222 -0.783
202303 -0.770 127.348 -0.783
202306 -0.500 128.729 -0.503
202309 -0.650 129.860 -0.648
202312 -0.660 129.419 -0.660

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Lisata Therapeutics  (NAS:LSTA) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Lisata Therapeutics Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Lisata Therapeutics's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Lisata Therapeutics (Lisata Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
110 Allen Road, 2nd Floor, Basking Ridge, NJ, USA, 07920
Lisata Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapies for the treatment of advanced solid tumors and other major diseases.
Executives
David W. Slack director, officer: President & CBO 110 ALLEN ROAD, 2ND FLOOR, BASKING RIDGE NJ 07920
Heidi Henson director 2173 SALK AVENUE, SUITE 250, PMB#052, CARLSBAD CA 92008
Mohammad Azab director C/O SUPERGEN, INC., 4140 DUBLIN BLVD., SUITE 200, DUBLIN CA 94568
Erkki Ruoslahti director P.O. BOX 544, BUELLTON CA 93427
Steven S Myers director 4695 MACAUTHUR COURT, EIGHTH FLOOR, NEWPORT BEACH CA 92660
Kristen K Buck officer: EVP, R&D and CMO 110 ALLEN ROAD, 2ND FLOOR, BASKING RIDGE NJ 07920
Todd C Girolamo officer: CLO, SVP of Corp Dev 110 ALLEN ROAD, 2ND FLOOR, BASKING RIDGE NJ 07920
Anne Clem Whitaker director 109 BRIERY BRANCH COURT, MORRISVILLE NC 27560
Michael H. Davidson director OMTHERA PHARMACEUTICALS, INC., 707 STATE ROAD, PRINCETON NJ 08540
Cynthia Schwalm director C/O G1 THERAPEUTICS, 700 PARK OFFICES DR, SUITE 200, P.O. BOX 110341, RESEARCH TRIANGLE PARK NC 27709
David J Mazzo director, officer: Chief Executive Officer 110 ALLEN ROAD, 2ND FLOOR, BASKING RIDGE NJ 07920
Joseph Talamo officer: SVP and CFO CALADRIUS BIOSCIENCES, INC., 800 WESTCHESTER AVENUE. STE N341, RYE BROOK NY 10573
Douglas W Losordo officer: See Remarks 13 FOX MEADOW RD, SCARSDALE NY 10583
Anford 10 percent owner P.O. BOX 5039, SIOUX FALLS SD 57117
Health Sanford 10 percent owner P.O. BOX 5039, SIOUX FALLS SD 57117

Lisata Therapeutics (Lisata Therapeutics) Headlines

From GuruFocus